Tandem Diabetes Care Inc(TNDM) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin delivery system with Basal-IQ Technology; t:slim X2 with control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Further, the company offers Sugarmate, a mobile app for people with diabetes who use insulin. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

Current Price

$84.14

RSI

10.968

Beta:

0.16161

February 24, 2021
16M

50.748 %
20.658 %
524.331 %
-103.377 %

$486,025,000
$362,227,000
$170,969,000
$96,260,000
$78,541,000
$72,850,000
34.177 %
111.867 %
77.612 %
22.560 %
7.812 %

$-36,282,000
$-24,604,000
$-122,560,000
$-73,025,000
$-83,462,000
$-72,408,000
-32.187 %
398.130 %
-40.417 %
14.292 %
-13.244 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.